Changes to our trading names and address – MSD and Organon & Co. read more

Changes to our trading names and address

Please note that in 2021, MSD will be spinning off products from its women’s health, legacy brands, and biosimilars franchises into a new independent, publicly traded company known as Organon & Co.

Due to legal entity separation in advance of this spin off, we now have two UK registered businesses, MSD and Organon. Organon & Co. is a wholly owned subsidiary of Merck & Co., Inc. of Kenilworth, New Jersey, USA.

As a result of the future spin-off of Organon, as well as our head offices moving to London in early 2021, you will begin to see some changes to references to our products, contact details, materials and statements over the coming months.


Addressing antibiotic resistance is more critical than ever.
Here’s why.

Since their development, antibiotics have transformed healthcare and saved countless lives globally. But rising levels of antimicrobial resistance (AMR) make current antibiotics less effective. There’s no single or simple solution to the complex problem of AMR, but we’re committed to investing our expertise and resources alongside our partners to get much-needed antibiotics to those who need them most. Lives are at risk, and the time to act is now.

True to our company’s longstanding tradition of preventing and treating infectious diseases, we’re proud to commit to invest $100 million over 10 years in the new AMR Action Fund. Through this ground-breaking partnership of leading pharmaceutical companies, philanthropies, development banks and multilateral organisations, we aim to bridge the gap between the innovative early antibiotic pipeline and patients. New antibiotics are urgently needed. With this new fund for antibiotic research and development, our collective aim is to bring two to four new antibiotics to patients and clinicians by the end of the decade.

Here are five key reasons to build on these collaborative efforts to address AMR:

1. New antibiotics are urgently needed; however, there are relatively few in development
2. Once new antibiotics are approved, they need to be used appropriately
3. We must track resistance trends and use the data to inform on prescribing
4. We need to think beyond human health
5. The time to act against AMR is now

Job code: GB-NON-02954Date of preparation: July 2020